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2. ABBREVIATIONS
ARIC: Atherosclerosis Risk In the Community Study
BNP: brain natriuretic peptide
CI: confidence interval
C-index: concordance index
DHS: Dallas Heart Study
DT: E-wave deceleration time
FHS: Framingham Heart Study
FPG: fasting plasma glucose
HbA1c: hemoglobin A1c (glycosylated hemoglobin)
HR: hazard ratio
Hs-TnT: high-sensitivity (cardiac) troponin T
ICD: International Classification of Diseases
IFG: impaired fasting glucose
IQR: interquartile range
LV: left ventricle / left ventricular
LVEF: left ventricular ejection fraction 
LVH: left ventricular hypertrophy
LVM: left ventricular mass
LVMI: left ventricular mass index
MESA: Multi-Ethnic Study of Atherosclerosis
MPP: Malmö Preventive Project
MPP-RES: Malmö Preventive Project Re-Examination Study
NFG: normal fasting glucose
NT-proBNP: N-terminal prohormone of brain natriuretic peptide
RWT: relative wall thickness
SCORE: Systematic COronary Risk Evaluation 
SHS: Strong Heart Study
TnI: (cardiac) troponin I
TnT: (cardiac) troponin T 
3. RESEARCH IN CONTEXT
Despite declining age-adjusted mortality rates, cardiovascular dis-
ease is still the leading cause of death worldwide (1). Traditional
cardiovascular risk stratification tools that employ clinical risk fac-
tors, including Systematic COronary Risk Evaluation (SCORE) and 
Framingham Risk Score, although easily applied, are limited by
their modest discriminative abilities (2-5). As such, robust cardio-
The Interplay between Fasting Glucose,  
Echocardiography, and Biomarkers:  
Pathophysiological Considerations and Prognostic 
Implications 
Manan Pareek 
DANISH MEDICAL JOURNAL   2 
 
 
vascular risk assessment, including our understanding of the com-
plex interplay between risk factors, in the primary preventive set-
ting, remains incomplete. Phenotypical heterogeneity may be even 
greater among subjects with hyperglycemic conditions, i.e., predi-
abetes and diabetes, which is troublesome, given the dramatic 
global rise in mean fasting glucose levels, and the strong associa-
tion with adverse cardiovascular outcomes (6-12). The unmet need 
for refinement or restratification of risk based on these conven-
tional prediction models is further emphasized by our entrance 
into the era of precision medicine after the realization that one size 
simply does not fit all (13-15). Potential tools for closing these gaps 
and increasing our understanding of the pathways from risk factors 
through subclinical changes to manifest disease include imaging 
modalities and circulating biomarkers (16-20). 
 
4. BACKGROUND 
4.1 Glycemic Status and Cardiovascular Disease 
Type 2 diabetes is a multifaceted, chronic disease, pathophysiolog-
ically characterized by a progressive decrease in pancreatic insulin 
secretion and a concomitant increase in peripheral insulin re-
sistance, leading to hyperglycemia. The condition may be diag-
nosed based on fasting or random plasma glucose, the 2-hour 
plasma glucose during a 75 g oral glucose tolerance test, or gly-
cated hemoglobin (HbA1c) (21-23). In most cases, a confirmatory 
test is required. Many individuals do not meet the formal criteria 
for diabetes, but have glucose levels that cannot be considered 
normal. These conditions, i.e., impaired fasting glucose (IFG) and 
impaired glucose tolerance, are labeled prediabetes and are asso-
ciated with a high risk of progression to manifest diabetes 
(21,23,24). Intermediate levels of HbA1c may be considered as pre-
diabetes as well (25). Type 2 diabetes has reached epidemic pro-
portions globally, and the burden continues to increase (26). This 
is worrisome, given the adverse contributions to health-related 
costs and disability-adjusted life years through its influence on mul-
tiple organ systems (12,27,28). The leading cause of death in dia-
betes is cardiovascular disease (29). There is a graded increase in 
cardiovascular risk with worsening glycemic status, and complica-
tions include coronary artery disease, heart failure, cerebrovascu-
lar disease, and peripheral artery disease (6-8,30-34). Therefore, 
diabetes is considered a major risk factor for, or perhaps even a 
risk equivalent to, cardiovascular disease (35-37).  
 
4.2. Left Ventricular Structure and Function  
Since the course from risk factors to manifest cardiovascular dis-
ease is highly variable, subclinical, i.e., asymptomatic anatomical 
and functional, alterations may resemble intermediate mechanis-
tic links connecting the two, and as such, potentially improve risk 
discrimination (38). The presence of subclinical cardiovascular 
damage significantly raises the likelihood of developing sympto-
matic cardiovascular disease (39-42). Two such examples include 
left ventricular hypertrophy (LVH) and diastolic dysfunction, both 
of which can be evaluated using transthoracic echocardiography. 
LVH is defined as an inappropriately increased left ventricular mass 
(LVM), whereas diastolic dysfunction is the inability of cardiac my-
ofibrils to rapidly or completely return to their resting length and 
is characterized by delayed active relaxation and increased LV stiff-
ness. The conditions are interrelated as diastolic abnormalities are 
commonly observed among persons with LVH (43-46). Further-
more, both conditions are frequently encountered in the general 
population (47-53) and are predictive of cardiovascular morbidity 
and mortality in subjects with and without diabetes (54-57). The 
risk may be further modified by the magnitude of LVM and the LV 
geometric pattern, categorized according to the absence or pres-
ence of LVH and the relative wall thickness (RWT), a measure of 
the relationship between LV wall thickness and cavity diameter 
(58-61). 
 
4.3. Potential Implications of Glycemic Status on Left Ventricular 
Structure and Function 
One explanation for the poor prognosis among patients with dia-
betes is their susceptibility to develop a distinct primary myocar-
dial condition, diabetic cardiomyopathy, predisposing them to an 
increased risk of heart failure (35). Diabetic cardiomyopathy is de-
fined as ventricular dysfunction in patients with diabetes, occur-
ring independently of hypertension, coronary artery disease, and 
other recognized causes and is characterized by increased LVM, 
concentric changes, and predominantly diastolic dysfunction (62-
66). These cardiac abnormalities are common findings among pa-
tients with diabetes and may result from continuous metabolic 
stress, in line with the observation that their prevalence and sever-
ity seem directly related to the duration of diabetes (55,67-75). In-
deed, the presence of subclinical cardiovascular damage in diabe-
tes may act as a significant risk modifier and translates to a 
substantially increased event risk (76-78). However, it remains con-
troversial whether there is a graded association between glycemic 
status, particularly when assessed in the fasting state, and LV struc-
tural and functional abnormalities, i.e., whether the risk increases 
along the diabetic continuum, from normal glycemic status 
through prediabetes to manifest diabetes (79-86). Importantly, alt-
hough abnormal glycemic status accentuates risk in patients with 
known heart failure, its prognostic impact on subclinical cardiac ab-
normalities in apparently healthy subjects is unknown (87-90).  
 
4.4. Cardiovascular Biomarkers 
Despite the high prevalence of subclinical cardiac abnormalities, 
routine echocardiographic screening among asymptomatic pa-
tients with diabetes is not recommended (91,92). The same applies 
to asymptomatic individuals without diabetes. The availability of 
circulating cardiovascular biomarkers, e.g., natriuretic peptides 
and cardiac troponins, and their link to key pathophysiological pro-
cesses, structural and functional myocardial alterations among 
others, makes their use as risk modifiers across the spectrum of 
cardiovascular risk theoretically attractive, even in subjects who 
have been stratified according to their echocardiographic findings 
(93-106). Brain natriuretic peptide (BNP) is released predominantly 
from ventricular myocytes in response to increased wall stress, i.e., 
volume expansion with resultant pressure overload, and has vaso-
dilatory and diuretic properties (107). Circulating levels of the 
physiologically inert N-terminal fragment of its prohormone (NT-
proBNP) may be measured instead (108). Cardiac troponins I (TnI) 
and T (TnT) form part of the contractile apparatus in myocytes and 
are released upon disruption of normal cell membrane integrity 
(109). Their myocardial specificity makes them the preferred mark-
ers of ischemia and necrosis; however, the introduction of high-
sensitivity troponin (hs-Tn) assays has facilitated detection of cir-
culating levels in a considerable proportion of individuals without 
established cardiovascular disease as well (110-112). Finally, natri-
uretic peptides and troponins may be independent predictors of 
adverse outcomes in subjects both with and without diabetes, but 
their overall contribution to risk prediction models, particularly in 
low risk, apparently healthy subjects, is less clearly established 
(16,17,113-131). 
 
4.5. Potential Implications of Glycemic Status on Cardiovascular 
Biomarkers 
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Patients with diabetes are prone not only to heart failure, but also 
coronary artery disease, which is often silent (6-8,35). In fact, ad-
verse cardiac alterations may already be present at the time of di-
agnosis of diabetes (132,133), making NT-proBNP and hs-TnT ra-
tional candidates for biomarkers in this setting. Nevertheless, 
glycemic status may affect the strength of the association between 
biomarkers and echocardiographic findings, perhaps implying that 
this should be taken into account when attempting biomarker-
based risk prediction (134,135). The proportion of individuals with 
elevated concentrations of cardiovascular biomarkers may further 
be higher in the presence of diabetes, but seems to be influenced 
by diabetes duration and risk factor burden 
(98,116,121,123,128,136-139), and, similar to that noted for echo-
cardiographic abnormalities, it is unclear whether hyperglycemia 
and biomarker concentrations exhibit a graded relationship (139-
143). Finally, it is uncertain whether the predictive capabilities of 
NT-proBNP and hs-TnT differ across the glycemic spectrum, in ap-
parently healthy subjects.  
 
5. OBJECTIVES 
1. To examine whether greater fasting plasma glucose (FPG) levels 
were independently associated with LVM and/or geometric pat-
tern, in apparently healthy, elderly subjects with preserved LV ejec-
tion fraction (LVEF). 
 
2. To examine whether greater FPG levels were associated with LV 
diastolic dysfunction, independently of increased left ventricular 
mass index (LVMI), in apparently healthy, elderly subjects with pre-
served LVEF. 
 
3. To examine whether FPG levels modified the prognostic role of 
abnormal LVM, geometric pattern, and diastolic dysfunction, in 
predicting cardiovascular morbidity and mortality, in apparently 
healthy, elderly subjects with preserved LVEF. 
 
4. To examine whether greater FPG levels were independently as-
sociated with concentrations of NT-proBNP and hs-TnT, in appar-
ently healthy, elderly subjects with preserved LVEF. 
 
5. To define the incremental prognostic value of NT-proBNP and 
hs-TnT for predicting incident cardiovascular outcomes, beyond 
traditional risk factors and subclinical echocardiographic abnor-
malities, in apparently healthy, elderly subjects with preserved 
LVEF. Additionally, to explore the associations of NT-proBNP and 
hs-TnT with key echocardiographic measures of LV structure and 
function, including effects of FPG, in these subjects. 
 
6. To examine whether greater FPG levels modified the prognostic 
abilities of NT-proBNP and hs-TnT in predicting cardiovascular mor-
bidity and mortality, in apparently healthy, elderly subjects with 
preserved LVEF. 
 
6. METHODS 
6.1. Study Population 
The study population was derived from the echocardiography sub-
sample (n=1,792) of the Malmö Preventive Project Re-Examination 
Study (MPP-RES) (2002-2006, n=18,238) (82). MPP-RES was the 
second phase of the Malmö Preventive Project (MPP) (1974-1992, 
n=33,346), a population-based screening program that included in-
habitants from Malmö, Sweden, who belonged to prespecified 
birth cohorts between 1921-1949 (144). All participants answered 
a computer-based, self-administered questionnaire on lifestyle 
and medical history, including medication. Blood pressure and 
heart rate were recorded twice after 5 minutes of supine rest, with 
values averaged for the analyses. Height, weight, waist and hip cir-
cumferences were measured, and body mass index and body sur-
face area (DuBois formula) were calculated. Blood samples were 
drawn after an overnight fast for analysis of plasma glucose, 
plasma lipids, and biobank storage for genetic analysis. Additional 
blood samples for cardiovascular biomarker assessments were 
drawn at the time of echocardiography, approximately 6 months 
after the initial screening visit. Samples were stored at -20°C. 
 
Subjects, who underwent echocardiography, were randomly cho-
sen from the three categories defined by baseline FPG, i.e., normal 
fasting glucose (NFG), IFG, and diabetes, including use of anti-dia-
betic medication, with oversampling in the two latter groups. The 
original echocardiography subsample was stratified into patients 
(defined as individuals with known cardiovascular disease (n=300), 
those who were on cardiovascular (n=864), anti-diabetic (n=329), 
or lipid-lowering medication (n=464), or had a reduced LVEF < 50% 
(n=99)) and apparently healthy subjects, the latter being the focus 
of this thesis. Slight between-paper sample size variations were 
due to certain additional exclusion criteria, including missing echo-
cardiographic variables (n=158), missing biomarkers (n=31), or in-
complete follow-up (n=6), but comprised of 670-693 subjects. 
 
MPP-RES was approved by the Regional Ethical Review Board and 
conducted in accordance with the Declaration of Helsinki. All par-
ticipants provided written informed consent.  
 
6.2. Fasting Plasma Glucose 
The majority of analyses took into account the aforementioned 
FPG-based selection of study subjects. Excluding those already on 
anti-diabetic medication, the definitions of NFG, IFG, and diabetes 
resembled the World Health Organization criteria (21): NFG: a sin-
gle FPG ≤ 6.0 mmol/L; IFG: a single FPG between 6.1-6.9 mmol/L, 
or one measurement 7.0-11.0 mmol/L and a separate measure-
ment ≤ 6.9 mmol/L; newly diagnosed diabetes: a single FPG ≥ 11.1 
mmol/L or two separate measurements ≥ 7.0 mmol/L. Given the 
age-range of the study population, it was presumed that all cases 
comprised of type 2 diabetes, and no clear distinction was made 
throughout this thesis or its related publications. 
 
6.3. Echocardiography 
Six experienced technicians (biomedical scientists) performed all 
echocardiograms using either a 3V2c transducer (Acuson Sequoia, 
Mountain View, CA, USA) or an S3 transducer (Sonos 5500 Philips, 
Andover, MA, USA) and further did offline analyses of the images, 
using a mean of 3-5 cycles. Intra- and interobserver variabilities 
have been reported previously (82). 
 
LVEF estimates were based on visual quantification. For LVM as-
sessment, end-diastolic, 2-dimensional linear measurements in the 
parasternal long-axis view, at the tips of the mitral valve leaflets, 
perpendicular to the LV long axis, were used (46). Calipers were 
positioned on the interface between myocardial wall and cavity 
and the interface between myocardial wall and pericardium, re-
spectively, obtaining the thickness of the interventricular septum, 
LV internal diameter, and thickness of the posterior wall. The Dev-
ereux formula was used for LVM calculation, with LVMI obtained 
by indexing for body surface area. Cut-offs employed for LVH were 
LVMI > 95 g/m2 (females) and > 115 g/m2 (males). LV geometric 
characterization was achieved by combining LVMI and relative wall 
thickness (RWT, (2*posterior wall thickness)/LV internal diameter): 
normal: absence of LVH and RWT ≤ 0.42; concentric remodeling: 
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absence of LVH and RWT > 0.42; eccentric LVH: presence of LVH 
and RWT ≤ 0.42; concentric LVH: presence of LVH and RWT > 0.42. 
 
For evaluation of LV diastolic function, transmitral pulsed Doppler 
flow with a 1-3 mm sample volume placed between the tips of the 
mitral valve leaflets and tissue Doppler imaging with the sample 
volume positioned within 1 cm of the septal and lateral borders of 
the mitral annulus, both in the apical four-chamber view, were 
used (44). E, A, and E-wave deceleration time (DT) were obtained 
by pulsed Doppler imaging, and septal and lateral é by tissue Dop-
pler imaging. Age-appropriate partitions of these parameters were 
then used for classification: normal diastolic function: septal é ≥ 8 
cm/s and/or lateral é ≥ 10 cm/s; diastolic dysfunction: septal é < 8 
cm/s and lateral é < 10 cm/s; grade 1 dysfunction: diastolic dys-
function + DT ≥ 240 ms, E/A ratio < 0.8, averaged E/é ratio ≤ 12; 
grade 2 dysfunction: diastolic dysfunction + DT 140-240 ms, E/A ra-
tio 0.8-1.5, averaged E/é ratio ≥ 9; grade 3 dysfunction: diastolic 
dysfunction + DT < 140 ms, E/A ratio > 1.5, averaged E/é ratio ≥ 13. 
All cases of E/é ratio < 9 were classified as normal (DT < 240ms and 
E/A ratio ≥ 0.8), or grade 1 dysfunction (the remainder). In case of 
E/é ratio ≥ 9 and ≤ 12, subjects were only categorized as grade 1 or 
grade 2 dysfunction if both DT and E/A ratio fitted the same cate-
gory, with the remainder labeled undetermined diastolic dysfunc-
tion. If E/é ratio was > 12, subjects were categorized as grade 2 or 
3 diastolic dysfunction, which were grouped together for the anal-
yses, due to the low number of subjects with grade 3 dysfunction. 
Finally, planimetri in the apical four-chamber view during end-sys-
tole allowed for estimation of left atrial area. 
 
6.4. Biomarkers 
NT-proBNP was measured with an electrochemiluminescence im-
munoassay (Elecsys, Roche Diagnostics, Basel, Switzerland) at the 
Department of Clinical Chemistry, Akershus University Hospital, 
Lorenskog, Norway. An elevated concentration was defined as ≥ 15 
pmol/L. Hs-TnT was analyzed at the Department of Clinical Bio-
chemistry, Regional Hospital of Northern Jutland, Hjørring, Den-
mark, between May-June 2013, using an electrochemilumines-
cence immunoassay (Elecsys, Roche Diagnostics, Basel, 
Switzerland). A concentration ≥ 14 ng/L (99th percentile of a 
healthy reference population) was used as partition. 
 
6.5. Outcomes 
In papers III-IV, a composite of coronary events (myocardial infarc-
tion, stable ischemic heart disease, percutaneous coronary inter-
vention, coronary artery bypass grafting), heart failure, stroke, and 
all-cause mortality constituted the primary clinical outcome. Non-
fatal events were defined according to International Classification 
of Diseases (ICD-9 and ICD-10) codes, with validities in the Swedish 
National Inpatient Register previously reported (145). Mortality 
data were obtained through the National Registry on Causes of 
Mortality at the Swedish Central Bureau of Statistics. Follow-up 
was terminated on December 31, 2014. 
 
6.6. Statistical Methods 
The statistical software packages IBM SPSS Statistics versions 22-
23 (IBM, Armonk, NY, USA) and Stata/IC versions 13-14 (StataCorp 
LP, College Station, TX, USA) were used for all analyses. 
 
6.6.1. Summary Statistics 
Continuous variables were plotted as histograms, and distributions 
were visually inspected. Means, medians, skewness, and kurtosis 
were examined as well. Summary statistics were presented as 
means and standard deviations (variables with a clear or approxi-
mate Gaussian distribution) or medians and interquartile ranges 
(IQR) (variables with a clear non-Gaussian distribution). Categorical 
variables were presented as counts with corresponding percent-
ages. Group-wise comparisons were performed using independent 
samples t-test, one-way analysis of variance, Mann-Whitney U 
test, Kruskal-Wallis test, Pearson’s χ2-test, and Fisher’s exact test, 
as appropriate.  
 
6.6.2. Cross-Sectional Analyses  
In papers I-II, associations between echocardiographic variables 
and risk factors were examined using multivariable linear regres-
sion, binary logistic regression, and ordinal logistic regression mod-
els. In all cases, potential explanatory variables underwent univar-
iable analysis. Variables that were statistically significant or 
deemed clinically appropriate, including FPG category, were en-
tered into the final multivariable regression models, with applica-
tion of stepwise backward elimination for optimization (P-reten-
tion < 0.20 except for FPG category, which was kept in the models 
regardless of its P-value). Correlations between LV structure (mass 
and geometry) and diastolic function were further tested with 
Pearson’s product moment correlation (r) or Kendall’s tau-b (τ). In 
paper IV, associations between biomarkers and echocardiographic 
variables were assessed using sex- and age-adjusted multivariable 
linear regression models or binary logistic regression models. Mod-
erately to severely positively skewed variables (DT, E/A ratio, aver-
aged E/é ratio, NT-proBNP, and hs-TnT) were natural logarithmi-
cally transformed before inclusion in the regression models. 
 
6.6.3. Survival Analyses 
In papers III-IV, the risk associated with abnormal LV structure and 
function, and abnormal biomarker levels, respectively, were tested 
using Cox proportional-hazards regression models, with time to 
first composite endpoint as the underlying timescale. The propor-
tional-hazards assumption was examined using Schoenfeld residu-
als. Possible covariates included SCORE variables (age, sex, smok-
ing status, systolic blood pressure, total cholesterol), kidney 
function (cystatin C), FPG category, and presence of LVH and/or 
grade 2 or 3 diastolic dysfunction. For biomarkers, hazard ratios 
(HR) were reported for both the assay-specific cut-offs and the up-
per quartile versus the three lower quartiles.  
 
6.6.4. Discrimination and Reclassification 
In paper IV, discrimination abilities for prediction models, with and 
without addition of the biomarkers as continuous variables, were 
described and compared using Harrell’s concordance index (C-in-
dex), with the assumption that in case of two simultaneously ter-
minating lifetimes, neither could be said to have survived the other 
(uncensored policy) (146). The ability of each biomarker to improve 
prognostication was also tested with the continuous (category-
free) net reclassification improvement, which is not affected by 
category cut-offs and event rates (147). 
 
6.6.5. Interaction Analyses 
Interactions (effect modifications) were tested using the likeli-
hood-ratio test for regression models with and without the inter-
action term and most often displayed using Forest plots. 
 
6.6.6. Statistical Significance 
A two-sided P-value < 0.05 was considered statistically significant. 
No adjustments for multiple comparisons were made, and all find-
ings are to be considered exploratory (hypothesis-generating). 
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7. RESULTS 
7.1. Paper I 
7.1.1. Left Ventricular Mass Index 
LVMI was significantly greater among subjects with diabetes than 
in subjects with NFG or IFG (mean 90 +/- 26 g/m2 vs. 85 +/- 20 g/m2; 
P = 0.01), but there was no significant difference between subjects 
with IFG versus NFG (mean 87 +/- 21 g/m2 vs. 84 +/- 19 g/m2; P = 
0.08). Although FPG category was not a significant predictor of 
LVMI on multivariable analysis (Table 1), greater LVMI was only as-
sociated with higher NT-proBNP levels among subjects with IFG or 
diabetes (P < 0.001 for interaction) (Figure 1). There was a weak 
correlation between LVMI and diastolic function (r = 0.171; P < 
0.001).  
 
7.1.2. Left Ventricular Hypertrophy and Geometry 
LVH in its entirety was not more commonly observed among sub-
jects with diabetes than those without (14% vs. 12%, P = 0.60). The 
adjusted multivariable regression model is shown in Table 2. As 
such, FPG category was not associated with LVH on multivariable 
analysis, but significantly interacted with the association between 
LVH and NT-proBNP (P = 0.01 for interaction) (Figure 2). LVH and 
diastolic function were weakly, albeit significantly, correlated (τ = 
0.185; P < 0.001). Of note, concentric LVH was significantly more 
prevalent among subjects with diabetes (11% vs. 6%, P = 0.03) and 
also displayed the strongest correlation with grade 2 or 3 diastolic 
dysfunction (τ = 0.280; P < 0.001), with a significant interaction 
analogous to that described for LVH (P = 0.02 for interaction). 
 
Table 1. Multivariable linear regression model for prediction of 
left ventricular mass index (adjusted r2 = 0.204). 
 
Abbreviation: NT-proBNP = N-terminal prohormone of brain natri-
uretic peptide.  
 
Figure 1. The association between NT-proBNP and left ventricu-
lar mass index, according to fasting plasma glucose category. 
 
P < 0.001 for interaction. 
Abbreviations: ES = estimate; CI = confidence interval; NT-proBNP 
= N-terminal prohormone of brain natriuretic peptide.  
Table 2. Binary logistic regression model for prediction of left 
ventricular hypertrophy (pseudo-r2 = 0.126). 
 
Abbreviation: NT-proBNP = N-terminal prohormone of brain natri-
uretic peptide. 
 
Figure 2. The association between NT-proBNP and left ventricu-
lar hypertrophy, according to fasting plasma glucose category. 
 
P = 0.01 for interaction. 
Abbreviations: ES = estimate; CI = confidence interval; NT-proBNP 
= N-terminal prohormone of brain natriuretic peptide.  
 
7.2. Paper II 
7.2.1. E/é 
E/é was significantly greater among subjects with diabetes than 
those without (median 8 (IQR: 6-11) vs. 7 (IQR: 6-10); P = 0.03), but 
lower among subjects with IFG than those with NFG (median 7 
(IQR: 6-9) vs. 8 (IQR: 6-10); P = 0.04). Moreover, FPG category was 
not a significant determinant of E/é on multivariable analysis (Ta-
ble 3), but did interact with the association between E/é and sys-
tolic blood pressure (P = 0.001 for interaction), E/é and NT-proBNP 
(P < 0.001 for interaction), and E/é and LVMI (P = 0.02 for interac-
tion) (Figure 3). The direction of the interaction for LVMI was the 
opposite of what was seen for systolic blood pressure and NT-
proBNP. 
 
7.2.2. Diastolic Dysfunction 
The prevalence of grade 2 or 3 diastolic dysfunction was signifi-
cantly greater among subjects with diabetes than those without 
(25% vs. 16%; P = 0.02), and there was no significant difference be-
tween subjects with IFG versus those with NFG (13% vs. 18%; P = 
0.08). As seen for E/é, FPG category was not a significant determi-
nant of overall diastolic function on multivariable analysis (Table 
4), but significantly interacted with the association between E/é 
and systolic blood pressure (P = 0.03 for interaction), and E/é and 
NT-proBNP (P = 0.005 for interaction) (Figure 4). 
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Table 3. Multivariable linear regression model for prediction of 
log(E/é) (adjusted r2 = 0.317). 
 
 
Figure 3. The associations between risk factors and E/é, accord-
ing to fasting plasma glucose category. For visual purposes, the 
β-coefficients are shown for every 10-unit increase. 
 
Systolic blood pressure: P = 0.001 for interaction; NT-proBNP: P < 
0.001 for interaction; LVMI: P = 0.02 for interaction. 
Abbreviations: ES = estimate; CI = confidence interval; NT-proBNP 
= N-terminal prohormone of brain natriuretic peptide. 
  
Table 4. Ordered logistic regression model for prediction of 
worse diastolic function (pseudo-r2 = 0.158). 
 
 
Figure 4. The associations between risk factors and worse dias-
tolic function, according to fasting plasma glucose category. For 
visual purposes, the odds ratios are shown for every 10-unit in-
crease. 
 
Systolic blood pressure: P = 0.03 for interaction; NT-proBNP: P = 
0.005 for interaction. 
Abbreviations: ES = estimate; CI = confidence interval; NT-proBNP 
= N-terminal prohormone of brain natriuretic peptide.  
 
7.3. Paper III 
7.3.1. Fasting Plasma Glucose 
Although a graded, positive relationship between FPG category 
and outcome was indicated, this was not statistically significant: 
unadjusted analyses; NFG: baseline; IFG: HR, 1.14 (95% CI: 0.79-
1.66), P = 0.47; diabetes: HR, 1.32 (95% CI: 0.83-2.10), P = 0.25 (P = 
0.23 for trend) (Table 5 and Figure 5). 
 
7.3.2. Left Ventricular Mass and Geometry 
LVMI was not significantly associated with cardiovascular event 
risk (HR, 1.05 (95% CI: 0.97-1.14) per 10 g/m2 increase, P = 0.20). 
Similar results were observed for LVH (HR, 1.36 (95% CI: 0.85-2.09), 
P = 0.21) and for the individual geometric patterns (P ≥ 0.09 for all) 
(Table 5 and Figure 6). However, a significant interaction was 
found between FPG category and concentric LVH (P < 0.001 for in-
teraction), i.e., concentric LVH only predicted risk among subjects 
with IFG or diabetes (Figure 7). 
 
7.3.3. Diastolic Dysfunction 
Greater E/é (HR, 1.06 (95% CI: 1.01-1.11), P = 0.02), any diastolic 
dysfunction (HR, 1.66 (95% CI: 1.18-2.32), P = 0.003), grade 1 dys-
function, and grade 2 or 3 dysfunction (P ≤ 0.01 for both) were all 
significantly associated with an increased event risk on univariable 
analysis, whereas undetermined dysfunction was not (P = 0.97) (P 
= 0.002 for trend) (Table 5 and Figure 8). FPG category significantly 
interacted with the association between adverse risk and any dias-
tolic dysfunction, grade 2 or 3 dysfunction, and undetermined dys-
function (P ≤ 0.04 for all interactions), with diastolic dysfunction 
being a better predictor of adverse risk among subjects with hyper-
glycemia (Figure 7). 
 
Table 5. Unadjusted and adjusted hazard ratios for fasting 
plasma glucose and echocardiographic measures of left ventricu-
lar structure and function (composite of coronary events, heart 
failure, stroke, and all-cause mortality). 
DANISH MEDICAL JOURNAL   7 
 
 
 
a)Adjusted for SCORE variables (age, sex, smoking status, systolic 
blood pressure, total plasma cholesterol) 
b)Reference category = normal fasting glucose 
c)Reference category = absence of left ventricular hypertrophy 
d)Reference category = normal geometric pattern 
e)Reference category = normal diastolic function 
Abbreviations: HR = hazard ratio; CI = confidence interval. 
 
Figure 5. Kaplan-Meier survival curves for the composite of coro-
nary events, heart failure, stroke, and all-cause mortality, ac-
cording to fasting plasma glucose category. 
 
 
 
Figure 6. Kaplan-Meier survival curves for the composite of coro-
nary events, heart failure, stroke, and all-cause mortality, ac-
cording to the absence or presence of left ventricular hypertro-
phy. 
 
 
Figure 7. The associations between echocardiographic measures 
and the composite of coronary events, heart failure, stroke, and 
all-cause mortality, according to fasting plasma glucose cate-
gory. 
 
All hazard ratios are adjusted for SCORE variables (age, sex, smok-
ing status, systolic blood pressure, total plasma cholesterol). No 
events occurred in the group of subjects with NFG and concentric 
LVH (n=16); therefore, that subgroup is not depicted in the figure.  
Abbreviations: HR = hazard ratio; CI = confidence interval. 
 
Figure 8. Kaplan-Meier survival curves for the composite of coro-
nary events, heart failure, stroke, and all-cause mortality, ac-
cording to left ventricular diastolic function. 
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7.4. Paper IV 
7.4.1. N-terminal Prohormone of Brain Natriuretic Peptide 
NT-proBNP concentrations did not significantly differ between sub-
jects with and without diabetes (median 8 (IQR: 5-16) pmol/L vs. 8 
(IQR: 5-15) pmol/L; P = 0.46), but were significantly lower among 
subjects with IFG (median 7 (IQR: 4-13) pmol/L) than among those 
with NFG (median 10 (IQR: 5-18) pmol/L; P < 0.001 for difference) 
or diabetes (median 8 (IQR: 5-16) pmol/L; P = 0.009 for difference). 
However, IFG did not remain significantly associated with NT-
proBNP on multivariable analysis (Table 6), and there were no sig-
nificant interactions. 
 
7.4.2. High-Sensitivity Troponin T 
Hs-TnT concentrations were significantly greater among subjects 
with diabetes than those with NFG or IFG (median 9 (IQR: 6-11) 
ng/L vs. 7 (IQR: 5-9) ng/L; P < 0.001), but there was no difference 
between subjects with IFG and NFG, respectively (median 7 (IQR: 
5-9) ng/L vs. 7 (IQR: 5-9) ng/L; P = 0.87). Furthermore, hs-TnT was 
significantly greater among subjects with diabetes on multivariable 
analysis, although without any significant interactions (Table 7). 
 
7.4.3. Echocardiographic Correlates 
Both NT-proBNP and hs-TnT displayed significant associations with 
several echocardiographic measures, particularly those of LV struc-
ture, although effect sizes were generally unimpressive. Associa-
tions with concentric LVH were stronger than those for eccentric 
LVH. Among measures of diastolic function, the most consistent re-
sults were observed for grade 2 or 3 diastolic dysfunction. Table 8 
shows an extract of these associations. The effects of FPG on asso-
ciations between NT-proBNP and echocardiographic measures 
have been addressed in previous sections. In addition, FPG signifi-
cantly interacted with the association between hs-TnT and LVMI (P 
= 0.02 for interaction) and LVH (P = 0.04 for interaction), but not 
E/é (P > 0.99 for interaction) and diastolic function (P = 0.73 for 
interaction) (Figures 9 and 10). 
 
7.4.4. Prediction of Cardiovascular Events 
Subjects with high concentrations (upper quartile) of NT-proBNP 
or hs-TnT were at greater risk compared to those with low concen-
trations (lower three quartiles) (Figures 11 and 12). The addition of 
NT-proBNP to traditional risk factors, fasting glucose, cystatin C, 
and echocardiography provided a significant discrimination im-
provement for prediction of cardiovascular events (C-index: 0.721 
vs. 0.714, P = 0.045) and a positive net reclassification improve-
ment. However, no such isolated benefit was found for hs-TnT (C-
index: 0.715 vs. 0.714; P = 0.82) (Table 9).  
7.4.5. Prognostic Impact of Fasting Plasma Glucose on N-terminal 
Prohormone of Brain Natriuretic Peptide 
Although the prognostic ability of NT-proBNP seemed stronger 
among subjects with diabetes, no significant interactions were de-
tected (P ≥ 0.24) (Figure 13).  
 
7.4.6. Prognostic Impact of Fasting Plasma Glucose on High-Sen-
sitivity Troponin T 
Similar to NT-proBNP, a stronger prognostic ability of hs-TnT 
among subjects with diabetes was indicated, but without any sig-
nificant interactions (P ≥ 0.23) (Figure 13). 
 
Table 6. Multivariable linear regression model for prediction of 
log(NT-proBNP) (adjusted r2 = 0.290). 
 
Abbreviation: NT-proBNP = N-terminal prohormone of brain natri-
uretic peptide.  
 
Table 7. Multivariable linear regression model for prediction of 
log(hs-TnT) (adjusted r2 = 0.260). 
 
Abbreviation: hs-TnT = high-sensitivity troponin T.  
 
Table 8. Age- and sex-adjusted associations between biomarkers 
and echocardiographic variables. 
 
For associations between two continuous variables, standardized 
β-coefficients (P-values in brackets) are reported. 
For associations between one categorical (echocardiography) and 
one continuous (biomarker) variable, β-coefficients for standard-
ized values of biomarkers (P-values in brackets) are reported.  
 
Figure 9. The association between hs-TnT and left ventricular 
mass index, according to fasting plasma glucose category. 
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P = 0.02 for interaction. 
Abbreviations: ES = estimate; CI = confidence interval; hs-TnT = 
high-sensitivity troponin T.  
 
Figure 10. The association between hs-TnT and left ventricular 
hypertrophy, according to fasting plasma glucose category. 
 
P = 0.04 for interaction. 
Abbreviations: ES = estimate; CI = confidence interval; hs-TnT = 
high-sensitivity troponin T.  
 
Figure 11. Kaplan-Meier survival curves for the composite of cor-
onary events, heart failure, stroke, and all-cause mortality, ac-
cording to NT-proBNP concentrations. 
 
Abbreviation: NT-proBNP = N-terminal prohormone of brain natri-
uretic peptide. 
Figure 12. Kaplan-Meier survival curves for the composite of cor-
onary events, heart failure, stroke, and all-cause mortality, ac-
cording to hs-TnT concentrations. 
 
Abbreviation: hs-TnT = high-sensitivity troponin T. 
 
Table 9. Hazard ratios, C-indices, and net reclassification im-
provement for NT-proBNP and hs-TnT (composite of incident 
coronary events, heart failure, stroke, and all-cause mortality). 
 
a)For prespecified cut-off 
b)For quartile 4 versus quartiles 1-3 
c)With versus without biomarker (continuous) 
d)For biomarker (continuous), bootstrapped confidence interval 
(1,000 replications) 
Model 1: Adjusted for age and sex 
Model 2: Adjusted for SCORE variables (age, sex, smoking status, 
systolic blood pressure, total plasma cholesterol) 
Model 3: Adjusted for SCORE variables, left ventricular hypertro-
phy and/or diastolic dysfunction 
Model 4: Adjusted for SCORE variables, fasting plasma glucose 
category, and cystatin C 
Model 5: Adjusted for models 3+4 
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Abbreviations: NT-proBNP = N-terminal prohormone of brain na-
triuretic peptide; hs-TnT = high-sensitivity troponin T; CI = confi-
dence interval.   
 
Figure 13. The associations between biomarker concentrations 
and the composite of coronary events, heart failure, stroke, and 
all-cause mortality, according to fasting plasma glucose cate-
gory. 
 
Additional interaction analyses for absence versus presence of di-
abetes were non-significant (P = 0.06 for both biomarkers (quar-
tile 4 versus quartiles 1-3)). 
 
8. DISCUSSION 
8.1. Impact of Glycemic Status on Left Ventricular Structure 
Manifest diabetes is generally regarded as an independent risk fac-
tor for increased LVMI (67-69,72); however, in accordance with the 
magnetic resonance imaging based results from the Multi-Ethnic 
Study of Atherosclerosis (MESA) (81), we did not see a graded as-
sociation between FPG category and LV structure. Conversely, tra-
ditional markers of hyperglycemia were associated with LVMI and 
RWT in both the Strong Heart Study (SHS) (79,84,85) and the Fram-
ingham Heart Study (FHS) (80). For example, De Marco et al. found 
progressively greater LVMI and RWT among obese adolescents and 
young adults with IFG or diabetes (84), Capaldo et al. observed 
greater LVMI and RWT in persons with isolated IFG or combined 
IFG and impaired glucose tolerance (85), and independent associ-
ations for impaired glucose tolerance were demonstrated in FHS 
(80). There are several possible methodological explanations for 
these inconsistencies. Despite IFG and impaired glucose tolerance 
being equally predictive of incident type 2 diabetes, the concord-
ance between these two categories is limited, and postload glu-
cose may better predict cardiovascular morbidity and mortality 
than fasting glucose (24). The development of adverse myocardial 
changes is temporally related to hyperglycemia (73,75), and the 
time spent with glycemic disturbances in our study was presuma-
bly short as we excluded subjects on anti-diabetic medication at 
the time of screening. In addition, data from SHS referred to a spe-
cific ethnic cohort, i.e., American Indians. Lastly, the importance of 
hyperglycemia may decrease with age, and the subjects in the pre-
sent study were on average older than those examined in SHS. Fur-
ther adding to the premise that the mode of assessment for glu-
cose metabolism and selected partitions are important factors to 
consider when attempting to demonstrate cardiovascular differ-
ences across the hyperglycemic spectrum, is a recent report from 
the Atherosclerosis Risk In the Community (ARIC) Study, which 
showed graded associations between LV abnormalities and glyce-
mic category, based on HbA1c, for some, but not all markers of LV 
structure, i.e., septal wall thickness and RWT were greater and LV 
internal diameter smaller, but LVMI was not significantly different 
in subjects with prediabetes versus those with normal glycemic 
status (86).   
 
In our study, diabetes was primarily associated with concentric 
LVH, and concentric LVH further displayed the strongest correla-
tion with diastolic dysfunction. Concentric changes are more prev-
alent in the setting of hyperglycemia (67-69,79,80), and concentric 
LVH may further be associated with a higher risk of morbidity and 
mortality than the other LV geometric patterns (59-61). Addition-
ally, the effects of antihypertensive treatment on LVH regression 
seem attenuated among patients with diabetes (148,149), and the 
cardiovascular role of isolated, strict glucose-lowering is also un-
clear (150-155). Formation of advanced glycation end products and 
their cross-linking with collagen may in part account for these 
treatment failures (156). All things considered, the presence of LVH 
in diabetes may represent a more harmful type of LVH than that 
seen in other conditions. 
 
8.2. Impact of Glycemic Status on Left Ventricular Function 
Evidence regarding the association between glycemic status and LV 
diastolic function is less abundant than that for LV structure. Simi-
lar to the observations for LV structure, and in line with SHS (84), 
we did not find a graded effect of FPG category on diastolic func-
tion. In contrast, in the Diagnostic Trial on Prevalence and Clinical 
Course of Diastolic Dysfunction and Diastolic Heart Failure, the 
prevalence and severity of diastolic dysfunction increased along 
the diabetic continuum (83). However, in the latter study, all indi-
viduals without known diabetes were subjected to an oral glucose 
tolerance test, the implications for which have been described in 
the previous section, and the study population was further en-
riched by selecting subjects with risk factors for or even manifest 
heart failure. Finally, in ARIC, the majority of measures of diastolic 
function did not significantly differ between individuals with nor-
mal glycemic status and prediabetes, whereas significant changes 
were reported for most measures when comparing patients with 
diabetes versus those without (86). Since diabetes per se is consid-
ered a risk factor for diastolic dysfunction, we speculate that the 
significant differences observed between subjects with diabetes 
and those without might be due to a threshold effect of hypergly-
cemia on myocardial stiffening. 
 
Higher systolic blood pressure was predominantly associated with 
worse diastolic function among subjects without diabetes, 
strengthening the idea of an independent effect of diabetes, 
whereas greater LVMI showed a significantly stronger association 
with worse diastolic function among patients with abnormal glyce-
mic status. It is likely that hyperglycemia augments the myocardial 
stiffening caused by LVH, possibly through a reduction in coronary 
flow reserve, which has proven associations with LVH, diastolic 
dysfunction, and diabetes (157). Nevertheless, whether the lower 
coronary flow reserve among patients with diabetes is a direct con-
sequence of hyperglycemia or due to insulin resistance, endothe-
lial dysfunction, or increased sympathetic activity, is not known. 
Although the absence of an association between systolic blood 
pressure and diastolic function among subjects with diabetes disa-
grees with previously demonstrated synergistic effects of diabetes 
and hypertension (158), an explanation may be provided by the 
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Cardiovascular Continuum paradigm, i.e., ageing, whether physio-
logical or pathological, brought on by cardiovascular risk factors, 
including diabetes, ultimately results in the same adverse cardio-
vascular alterations, and accelerated effects are seen in the pres-
ence of multiple risk factors (159-161). This theory and our findings 
are supported by the strong relationship between age and diastolic 
function in this elderly cohort, a presumed late onset of hypergly-
cemia, and a probable dominating effect of diabetes over other 
cardiovascular risk factors. Lastly, a theoretical framework, com-
plementing the Cardiovascular Continuum, has been proposed, in 
which diastolic dysfunction can be considered the final common 
pathway for various conditions, including overweight, hyperten-
sion, and diabetes, which induce a state of inflammation, coronary 
microvascular endothelial dysfunction, and cardiomyocyte hyper-
trophy and stiffening (162). 
 
8.3. Prognostic Impact of Glycemic Status on Left Ventricular 
Structure and Function 
Several studies have examined the cross-sectional relationships 
between prediabetes, diabetes, and LV structural and functional 
alterations; however, we have demonstrated for the first time that 
glycemic status, in a graded fashion, modifies the risk of incident 
events associated with subclinical echocardiographic abnormali-
ties. Specifically, concentric LVH and diastolic dysfunction were 
more strongly associated with an adverse prognosis in subjects 
with IFG or diabetes compared to subjects with NFG. These obser-
vations fit well the aforementioned Cardiovascular Continuum con-
cept (159-161), including the tendency towards risk factor cluster-
ing in diabetes (12), not all of which can be adjusted for. Moreover, 
we used a composite endpoint, including all-cause mortality, and 
even non-cardiovascular mortality may be elevated among pa-
tients with diabetes (163). Still, the underlying mechanisms, specif-
ically on the cardiac level, remain speculative. As alluded to previ-
ously, the presence of LVH in diabetes may represent a more 
deleterious form of LVH, due to its often-concentric nature and 
strong association with hypertension and diastolic dysfunction, but 
notably, the results were independent of systolic blood pressure. 
These findings are also consistent with previously proposed theo-
ries regarding the etiology and pathogenesis of structural and func-
tional echocardiographic alterations in patients with diabetes, in-
cluding inflammation and endothelial dysfunction (162), decreased 
coronary flow reserve (157), and formation of advanced glycation 
end products (156).  
 
8.4. Impact of Glycemic Status on Cardiovascular Biomarker Con-
centrations 
Prior studies have shown higher hs-TnT concentrations among pa-
tients with diabetes compared to subjects without 
(98,116,121,137,138,142,143). Examples include the Dallas Heart 
Study (DHS), in which the proportion of patients with diabetes in-
creased across hs-TnT categories (98), and the Women’s Health 
Study, in which hs-TnT concentrations and the fraction with detect-
able hs-TnT concentrations, but not elevated above the upper ref-
erence limit, i.e., the 99th percentile, were significantly higher 
among women with a history of diabetes versus those without 
(116). Our results confirmed these observations in older, low risk 
individuals, but hs-TnT did not vary between subjects with NFG and 
IFG. Although such a difference was seen in ARIC (142), only glyce-
mic status defined by means of HbA1c, not FPG, was significantly 
associated with hs-TnT. Further supporting our results, and the 
prior notion that the method for measuring and defining glycemic 
status should be taken into consideration when exploring associa-
tions with subclinical cardiovascular disease, significant differences 
between subjects with diabetes versus those without, but not be-
tween normal glycemic status and prediabetes, defined as IFG or 
impaired glucose tolerance, were shown by Zheng et al. (143). Fi-
nally, the relationship between HbA1c and hs-TnT may be steepest 
in the narrow range that defines prediabetes, providing a rationale 
for the more robust findings for diabetes (142). Potential underly-
ing mechanisms for the increased hs-TnT levels in non-acute set-
tings largely mimic those proposed for hyperglycemia-related LV 
structural and functional alterations, including microvascular dys-
function or damage (164), advanced glycation end products (156), 
low grade inflammation (165), myocardial fibrosis (166), or per-
haps even silent epicardial coronary artery disease (167). 
 
The case may be more complicated for NT-proBNP since concen-
trations were lowest in the IFG group, and without any measurable 
difference between subjects with diabetes and NFG. Indeed, previ-
ous results concerning glycemic status have been somewhat incon-
sistent (136,139-141,168-172), while inverse relationships of natri-
uretic peptides with body mass index and other metabolic risk 
factors have been consistently shown in population-based studies, 
including FHS (168,171) and DHS (170). Wang et al. showed addi-
tive, negative effects of obesity and diabetes on BNP levels (168), 
whereas Das et al. found inverse associations between both BNP 
and NT-proBNP with body mass index and a closer correlation with 
lean mass than with fat mass (170). This suggests that the presence 
of natriuretic peptide clearance receptors in adipose tissue, which 
are believed not to bind NT-proBNP, is not the only explanation 
(173). Altered cardiac synthesis and/or secretion seems more 
probable (174), and sex may play an additional role (141,168). Fi-
nally, and in agreement with its hemodynamic properties, NT-
proBNP is elevated in the presence of subclinical cardiac damage 
(95-97,99-102,104-106,134,135), which is more common in the 
presence of diabetes. Although it is difficult to draw definite con-
clusions regarding the influence of isolated hyperglycemia on NT-
proBNP, lower concentrations should generally be expected, and 
interpretation in relation to the overall metabolic profile seems 
reasonable. 
 
8.5. Impact of Glycemic Status on the Associations between Echo-
cardiography and Cardiovascular Biomarkers 
Significant, albeit modest, correlations between biomarkers and 
echocardiography were expected in this apparently healthy cohort 
(98,100,134,135). This highlights the beliefs that individual bi-
omarkers cannot be recommended as screening tools solely for LV 
dysfunction due to limited sensitivity (94,97,98,101,175), that risk 
estimates based on imaging studies and circulating biomarkers 
should be considered complimentary (100,105), and further fits 
the said clinical and pathophysiological complexities associated 
with circulating levels of NT-proBNP and hs-TnT. We found 
stronger correlations with LV structure than with diastolic function, 
perhaps due to the inherent challenges associated with non-inva-
sive assessment of diastolic function (44,176). 
 
NT-proBNP concentrations were primarily related to LVMI and LVH 
among subjects with hyperglycemia, extending previous findings 
from the Hoorn Study, in which stronger cross-sectional associa-
tions between BNP and diastolic function, and BNP with temporally 
worsening diastolic function and increasing LVMI, were observed 
among patients with diabetes compared to those without 
(134,135). Possibly, the association between NT-proBNP and LV 
size only appeared stronger in subjects with IFG due to their lower 
NT-proBNP concentrations, whereas the robust association in pa-
tients with diabetes stemmed from relatively lower NT-proBNP 
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concentrations in relation to their higher prevalence of LV abnor-
malities (168,171,177-180). This lends support to the concept that 
similar NT-proBNP levels indicate a worse LV state and prognosis 
in diabetes. This could also apply to hs-TnT, despite its higher base-
line levels among patients with diabetes as similar patterns for 
LVMI and LVH were observed. It has further been speculated that 
an increased production of natriuretic peptides might precede 
overt echocardiographic abnormalities, resembling damage by the 
mechanisms mentioned previously (157,181,182). The fact that the 
interaction between NT-proBNP and E/é followed a reverse pat-
tern would support this concept as well as the hypothesis that LVH 
precedes diastolic dysfunction, i.e., the impact of hemodynamic 
measures on myocardial relaxation may fall beneath that of meta-
bolic factors, once LVMI has been sufficiently increased. Although 
this contradicts the findings from the Hoorn Study, their lack of 
Doppler measurements for assessment of diastolic function ob-
scures direct comparisons (134,135). 
 
8.6. Prognostic Impact of Glycemic Status on Cardiovascular Bi-
omarkers 
Troponins and natriuretic peptides deliver incremental prognostic 
information among high risk individuals, particularly those with 
known cardiovascular disease (128,183,184), but the evidence for 
apparently healthy subjects is ambiguous, i.e., very large sample 
sizes have usually been needed to show minor improvements, if 
any, in risk stratification for individual biomarkers 
(115,127,130,185), and there is further evidence of reporting bias 
(186). The observed modest model improvement provided by NT-
proBNP beyond clinical risk factors and structural and functional 
echocardiographic changes is intriguing and extends prior findings 
from MESA (99), DHS (100), and the Cardiovascular Health Study 
(105), in which LVH with concomitantly elevated concentrations of 
NT-proBNP and/or hs-TnT was associated with a more severe dis-
ease course. As an example, in DHS, which oversampled African 
Americans, NT-proBNP and hs-TnT provided incremental prognos-
tic value beyond, and interacted with, LVH determined by mag-
netic resonance imaging (100). The findings were independent of 
LVM, leading the authors to propose that elevations of these bi-
omarkers may represent adverse remodeling from LVH to manifest 
heart failure, not merely greater LVM in persons with higher bi-
omarker concentrations. Furthermore, NT-proBNP and hs-TnT dis-
played distinct correlations with markers of LV structure. Likewise, 
in our study, hs-TnT seemed a better predictor of LV diastolic func-
tion than NT-proBNP and vice versa. However, hs-TnT showed no 
benefit as an individual marker in our sample in its entirety, possi-
bly related to ethnicity, use of both LVH and diastolic dysfunction 
as the echocardiographic variable, and use of a composite end-
point, including all-cause mortality, which may not be accurately 
predicted by hs-TnT (127). 
 
Despite the interaction terms between biomarkers and FPG cate-
gory not reaching formal statistical significance, trends consistently 
favored a more robust predictive capability for both biomarkers 
among subjects with diabetes. Biomarker concentrations may fur-
ther be stronger predictors of risk than a history of symptomatic 
cardiovascular disease in patients with diabetes (128), and Zethe-
lius et al. found a greater discriminative ability for traditional risk 
factors, but lower utility of biomarkers, when comparing persons 
without established cardiovascular disease to those with (17). 
Kroon et al. showed a greater adjusted risk of adverse echocardio-
graphic changes among patients with diabetes versus those with-
out (135), and data from ARIC showed higher incidences of ele-
vated hs-TnT among individuals with prediabetes and diabetes, 
and that such elevations were related to incident cardiovascular 
disease (121). In fact, associations with incident heart failure and 
mortality were stronger than with coronary artery disease, in line 
with the postulated etiological differences between acute versus 
chronic troponin release. Collectively, the prognostic properties of 
traditional risk factors and biomarkers may differ per a priori risk, 
including glycemic status. 
 
Given the considerable interindividual differences in development 
and progression of adverse cardiovascular changes, concurrent 
measurement of biomarkers that resemble separate mechanistic 
pathways could, theoretically, enhance risk stratification. How-
ever, current data are less convincing for low risk subjects 
(16,17,113,115,128,183-185,187). Although slightly tangential to 
the objectives of this thesis, we tested a combination of three bi-
omarkers, i.e., NT-proBNP, hs-TnT, and growth-differentiation fac-
tor 15, and demonstrated a stepwise increase in risk. Overall model 
performance was augmented modestly, but significantly, confirm-
ing prior findings from the Uppsala Longitudinal Study of Adult 
Men (17), the Malmö Diet and Cancer Study (115), and the FIN-
RISK97 cohort (185), among others. As such, there may be a role 
for multimarker models in lower risk populations, and the prognos-
tic value seems to appear independently of echocardiographically 
determined LV structure and function. 
 
9. LIMITATIONS 
9.1. Study Population 
Despite the relatively high participation rate of 72% in MPP-RES, it 
may be argued that the study subjects did not represent a truly 
random population sample, since individuals who agree to partici-
pate in such screening studies may be healthier than the general 
population. The applicability of the results in females may be lim-
ited by the fact that 70% of subjects in the present study were 
male, and the generalizability to groups other than elderly Cauca-
sians is also unknown. Our exclusion of more than half of the orig-
inal study population to obtain a cohort of apparently healthy sub-
jects free from known cardiovascular disease and on no 
cardiovascular medications may have introduced another selection 
bias, i.e., healthy cohort effect. Additionally, the low event rate 
with associated low power to detect prognostic associations was a 
limitation and prompted us to use a composite endpoint. It should 
be noted, however, that these limitations would tend to decrease 
rather than increase the sensitivity of our analyses, thus highlight-
ing the importance of the positive findings.  
 
9.2. Fasting Plasma Glucose 
The subgroup division was based on FPG, in most cases a single 
measurement. The addition of an oral glucose tolerance test or 
HbA1c measurements would have been desirable for several rea-
sons. For instance, impaired glucose tolerance and diabetes de-
fined by oral glucose tolerance testing are more common among 
women than men, whereas IFG is more often seen in men (24). FPG 
exhibits greater fluctuation than HbA1c, which provides an esti-
mate of the average glucose levels, and possibly sustained myocar-
dial affection, over a 2-3-month period (22); however, the latter 
was not routinely measured during the screening process due to 
financial limitations. Furthermore, prognostic associations might 
have been affected by subjects having been captured early during 
hyperglycemia, and use of anti-diabetic medication, perhaps initi-
ated soon after screening, could not be accounted for. Therefore, 
the use of FPG would tend to decrease the sensitivity, not specific-
ity, of the analyses. 
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9.3. Echocardiography 
2D-guided linear LV measurements have well-documented prog-
nostic properties and are particularly useful for studying large pop-
ulations. However, the method utilizes basal dimensions only, and 
LV changes that occur along the long axis of the chamber cannot 
be accounted for. The Devereux formula for calculating LVM as-
sumes normal LV geometry and cubes the linear measurements 
(46). Consequently, even small errors may significantly influence 
the estimated mass. The exclusion of individuals with reduced LVEF 
< 50 % is likely to have accounted for distorted LV geometry except 
discrete upper septal thickening, which is particularly common in 
elderly, hypertensive subjects (188). It is possible that in our study 
population, this phenomenon may have attenuated the prognostic 
role of LVMI. 
 
Preload increases é velocity in normal subjects, and as such, its util-
ity in these individuals may be limited (189). In addition, lateral E/é 
may be better than septal E/é for estimation of LV filling pressures 
in subjects with preserved LVEF > 50%. However, we used the av-
eraged E/é due to lack of information on regional dysfunction. Fi-
nally, a more robust grading of diastolic dysfunction could have 
been attained if we had been able to include the left atrial volume 
index (44). Nevertheless, we used strict criteria for E/é, and the un-
certain prognostic differences between grade 1 dysfunction and 
grade 2 or 3 dysfunction in our cohort serve as a general reminder 
of the difficulties associated with echocardiographic diagnosis and 
grading of diastolic dysfunction (176). 
 
Therefore, it may be argued, that these limitations pertaining to 
echocardiography, would, similar to what was noted for the study 
population and FPG, tend to increase the likelihood of false nega-
tive findings. 
 
9.4. Biomarkers 
Biomarkers were examined in blood samples which had been fro-
zen for up to 10 years, potentially influencing concentrations and 
presumably leading to underestimation of their prognostic abilities 
(190). 
 
10. CONCLUSIONS 
1. Subjects with newly diagnosed diabetes had greater LVMI and a 
higher prevalence of concentric LVH, but only on univariable anal-
ysis.  
 
2. Subjects with newly diagnosed diabetes had greater E/é and a 
higher prevalence of grade 2 or 3 diastolic dysfunction, but the as-
sociations were not independent of LVMI. FPG category signifi-
cantly interacted with the association between E/é and LVMI, and 
LVMI was primarily associated with higher E/é in subjects with IFG 
or diabetes. 
 
3. Subclinical echocardiographic abnormalities, par-ticularly those 
of LV diastolic function, were associated with an increased risk of 
incident cardiovascular events. FPG category was not by itself as-
sociated with the outcome, but modified the prognostic role of 
concentric LVH and diastolic dysfunction, i.e., these alterations 
were more strongly associated with adverse prognosis in subjects 
with IFG or diabetes. 
 
4. Subjects with IFG had significantly lower NT-proBNP concentra-
tions than subjects with NFG or newly diagnosed diabetes on uni-
variable, but not multivariable, analysis. Diabetes was inde-
pendently associated with higher hs-TnT concentrations on multi-
variable analysis. 
 
5. Subjects with high concentrations of NT-proBNP and hs-TnT 
were at greater risk of incident cardiovascular events compared to 
those with low concentrations. NT-proBNP provided a significant 
discrimination improvement beyond traditional risk factors and 
subclinical echocardiographic abnormalities, whereas hs-TnT did 
not. NT-proBNP and hs-TnT were significantly associated with sev-
eral echocardiographic parameters, particularly those of LV struc-
ture, and less so for diastolic function, but effect sizes were gener-
ally modest. Associations were modified by FPG category.  
6. FPG category did not significantly modify the prognostic role of 
NT-proBNP and hs-TnT, but the totality of the data suggests that 
glycemic status should be considered when interpreting biomarker 
concentrations. 
 
11. PERSPECTIVES 
Cardiovascular risk assessment in the primary preventive setting 
remains challenging and may be both affected and complicated by 
glycemic status. Numerous potential strategies have not been 
properly studied or validated, and most attempts to enhance risk 
stratification have yielded insignificant to modest effects. Given 
the results of this thesis, the following may be considered for fu-
ture observational and interventional research:  
 
1. The adverse myocardial alterations in diabetes might stem from 
extended exposure to hyperglycemia and obesity, and the pres-
ence of IFG may provide a window of opportunity to prevent or 
reduce LVH and diastolic dysfunction by halting progression into 
manifest diabetes. 
 
2. Targeting both systemic and cardiovascular comorbidities at an 
early stage, including blood pressure lowering, regression of LVH, 
glucose-lowering, weight reduction, lipid-lowering, and anti-in-
flammatory therapy, may delay the progression of subclinical dias-
tolic dysfunction to overt heart failure.  
 
3. Subclinical echocardiographic abnormalities may be particularly 
deleterious in subjects with hyperglycemia, represent a key mech-
anistic link between diabetes and overall cardiovascular risk, and 
may thus be used to enrich study populations in future clinical trials 
of such individuals.  
 
4. Different prognostic roles of traditional risk factors and bi-
omarkers according to a priori risk should be considered. Multi-
marker strategies may have a prognostic role among low risk sub-
jects, but there is a need for validation of specific biomarker 
combinations in different populations and across different risk cat-
egories.  
 
5. Biomarkers may be used to enrich study populations in future 
clinical trials of primary preventive strategies, regardless of base-
line glycemic status, but more data regarding the potential benefit 
of biomarker-based intervention, including initiation or intensifica-
tion of diagnostic, therapeutic, and monitoring strategies, is 
needed, particularly among low risk subjects. 
 
6. Biomarkers may be more representative of subclinical echocar-
diographic abnormalities among subjects with hyperglycemia, but 
should be considered complimentary, rather than as replacements 
to, echocardiography, regardless of glycemic status. 
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12. SUMMARY 
12.1. Background 
Traditional cardiovascular risk stratification tools that employ clin-
ical risk factors are limited by their modest discriminative abilities. 
As such, robust cardiovascular risk assessment, including our un-
derstanding of the complex interplay between risk factors, in the 
primary preventive setting, remains incomplete. Phenotypical het-
erogeneity may be even greater among subjects with hyperglyce-
mic conditions, i.e., prediabetes and diabetes, which is worrisome, 
given the dramatic global rise in mean fasting glucose levels, and 
the strong association with adverse cardiovascular outcomes. The 
unmet need for refinement or restratification of risk based on 
these conventional prediction models is only emphasized by our 
entrance into the era of precision medicine. Potential tools for clos-
ing these gaps and increasing our understanding of the pathways 
from risk factors through subclinical changes to manifest disease 
include echocardiography and circulating biomarkers.  
 
12.2. Objectives 
1) To examine whether greater fasting plasma glucose (FPG) levels 
were associated with left ventricular mass (LVM), geometric pat-
tern, diastolic function, and concentrations of N-terminal prohor-
mone of brain natriuretic peptide (NT-proBNP) and high-sensitivity 
cardiac troponin T (hs-TnT) in apparently healthy, elderly subjects 
with a preserved LV ejection fraction ≥ 50%; 2) To examine 
whether FPG levels modified the prognostic role of abnormal LVM, 
geometric pattern, diastolic dysfunction, NT-proBNP, and hs-TnT, 
in predicting cardiovascular morbidity and mortality; 3) To define 
the incremental prognostic value of NT-proBNP and hs-TnT for pre-
dicting incident cardiovascular outcomes, beyond traditional risk 
factors, glycemic status, and subclinical echocardiographic abnor-
malities; 4) To explore the associations of NT-proBNP and hs-TnT 
with key echocardiographic measures of LV structure and function, 
including the effects of FPG levels. 
 
12.3. Methods 
The thesis was based on a series of cross-sectional and prospective 
observational studies. The study population was derived from the 
echocardiography subsample (n=1,792) of the Malmö Preventive 
Project Re-Examination Study (MPP-RES) (2002-2006, n=18,238), a 
population-based screening program that included inhabitants 
from Malmö, Sweden, who belonged to prespecified birth cohorts 
between 1921-1949. Subjects, who underwent echocardiography, 
were randomly chosen from the three categories defined by base-
line FPG, i.e., normal fasting glucose, impaired fasting glucose, and 
diabetes, including use of anti-diabetic medication. Blood samples 
for cardiovascular biomarker assessments were drawn at the time 
of echocardiography and kept frozen until analysis. Outcome data 
were obtained through national and local registries. The original 
echocardiography subsample was stratified into patients and ap-
parently healthy subjects, the latter being the focus of this thesis. 
 
12.4. Results 
1) Subjects with diabetes had a greater prevalence of concentric LV 
hypertrophy (LVH), grade 2 or 3 diastolic dysfunction, and higher 
hs-TnT concentrations. Subjects with impaired fasting glucose had 
the lowest NT-proBNP concentrations. LVMI was primarily associ-
ated with diastolic function in subjects with hyperglycemia; 2) LV 
diastolic dysfunction was associated with an increased risk of inci-
dent cardiovascular events, but did not provide discriminative im-
provement. Concentric LVH and diastolic dysfunction were more 
strongly associated with adverse prognosis in subjects with hyper-
glycemia. High concentrations of NT-proBNP and hs-TnT predicted 
incident cardiovascular events, with no effect modification by FPG; 
3) NT-proBNP, but not hs-TnT, provided discriminative improve-
ment beyond traditional risk factors, FPG, and LVH and/or diastolic 
dysfunction; 4) NT-proBNP and hs-TnT were associated with sev-
eral echocardiographic parameters, but effect sizes were generally 
modest. Associations between biomarkers and echocardiographic 
measures were affected by hyperglycemia. 
 
12.5. Conclusions 
FPG influenced the interplay between subclinical echocardio-
graphic abnormalities, circulating biomarkers, and cardiovascular 
outcomes at multiple stages, in this cohort of apparently healthy, 
elderly subjects. Newly diagnosed diabetes, but not impaired fast-
ing glucose, was associated with adverse subclinical changes. The 
associations between structural echocardiographic abnormalities 
and biomarker concentrations were stronger in subjects with hy-
perglycemia. NT-proBNP, but not echocardiographic measures or 
hs-TnT, provided discriminative improvement on top of traditional 
cardiovascular risk factors. FPG further modified the prognosis re-
lated to echocardiographic alterations, but not that predicted by 
biomarkers. Therefore, FPG should be considered when assessing 
markers of subclinical cardiovascular alterations.  
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